

We claim

1. The process of manufacturing a pharmaceutical composition for the management of asthma (obstructive lung disease) comprises of incorporating cells of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative in a single formulation.
2. The pharmaceutically acceptable carrier as claimed in claim 1 is added in a way so as to have more than or equal to 1×10^5 mycobacterium w in a unitary dosage, more preferably equal to or more than 1×10^7 mycobacterium w in unitary dosage most preferably between 1×10^8 to 1×10^9 cells of mycobacterium w in a unitary dosage form.
3. The preservative as claimed in claim 1 is Thiomesol and is added to have final concentration of 0.01% w/v.
4. The process of manufacturing a pharmaceutical composition for the management of asthma ((obstructive lung disease) comprising the steps of incorporating disrupted cells of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative.
5. Disruption of mycobacterium w as claimed in claim 4 is done by sonication or high pressure fractionometer.
6. The process of manufacturing a pharmaceutical composition useful for the management of asthma (obstructive lung disease) comprising the steps of incorporating solvent extraction of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative.
7. Solvent extraction as claimed in claim 6 is done by using a solvent selected from chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea, etc.
8. The process of manufacturing a pharmaceutical composition for the management of asthma (obstructive lung disease) comprising of incorporating enzymatic extraction of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative .
9. The enzymes used for enzymatic extraction of cells of mycobacterium w is selected from lyticase and/or pronase.

10. The process of manufacturing a pharmaceutical composition for the management of asthma (obstructive lung disease) comprising admixing product of claim 1 with product of claim 4 and/or claim 6 and/ or claim 8.
11. The process of manufacturing a pharmaceutical composition for the management of asthma (obstructive lung disease) comprise of adding adjuvant to product of claim 1, claim 4, claim 6, claim 8 or claim 10.
12. The adjuvant as claimed in claim 17 is selected from mineral oil, mineral oil and surfactant, Ribi adjuvant, Titer-max, syntax adjuvant formulation, aluminum salt adjuvant, nitrocellulose adsorbed antigen, immune stimulating complexes, Gebru adjuvant, super carrier, elvax 40w, L -tyrosine, monatanide (manide -oleate compound), Adju prime, Squalene, Sodium phthalyl lipopoly saccharide, calcium phosphate, saponin, melanoma antigen, muramyl dipeptide(MDP) and like.
13. A pharmaceutical composition prepared according to claim 1 to 3, claim 4 and 5, claim 6 and 7, claim 8 and 9, claim 10, claim 11 and 12 useful for the management of asthma (obstructive lung disease).
14. A pharmaceutical composition prepared according to claim 1 to 3, claim 4 and 5, claim 6 and 7, claim 8 and 9, claim 10, claim 11 and 12 when administered prevents attacks of asthma (obstructive lung disease).
15. A pharmaceutical composition prepared according to claim 1 to 3, claim 4 and 5, claim 6 and 7, claim 8 and 9, claim 10, claim 11 and 12 when administered delays attacks of asthma (obstructive lung disease).
16. A pharmaceutical composition prepared according to claim 1 to 3, claim 4 and 5, claim 6 and 7, claim 8 and 9, claim 10, claim 11 and 12 when administered reduces the requirement of drugs used in management of asthma (obstructive lung disease).
17. A pharmaceutical composition prepared according to claim 1 to 3, claim 4 and 5, claim 6 and 7, claim 8 and 9, claim 10, claim 11 and 12 when administered improves lung function in presence/absence of other drugs.
18. Pharmaceutically acceptable carrier as claimed in claim 1, claim 4, claim 6, claim 8, claim 10, claim 11 contains surfactant.
19. The surfactant as claimed in claim 19 is selected from Tween 80 or triton x 100.

20. The concentration of surfactant as claimed in claim 19 and 20 is upto 0.4% preferably 0.1%.
21. Mycobacterium w as claimed in claim 1 to 20ch is a killed microorganism.